Centocor licenses Xencor tool to evaluate immunogenicity
Biotech company, Centocor Research and Development of Pennsylvania, US, has acquired a license to use Xencor's ImmunoFilter technology to evaluate the potential immunogenicity of therapeutic proteins.
Biotech company, Centocor Research and Development of Pennsylvania, US, has acquired a license to use Xencor's ImmunoFilter technology to evaluate the potential immunogenicity of therapeutic proteins.
Immunogenicity is the leading reason that biologics fail in the clinic. The ImmunoFilter technology developed by California-based Xencor is a predictive tool to identify the risk of immunogenicity in antibody and other protein therapeutic candidates.
Capable of assessing potential immunogenicity for more than 95% of the US population and based on empirical binding data, the technology is the first predictive method to use direct experimental measurements to catalogue the breadth of major histocompatability complex (MHC)-peptide interactions a key determinant of recognition of antigens by the immune system.